Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM.

Haematologica. 2019 Dec;104(12):e551-e554. doi: 10.3324/haematol.2018.209965. Epub 2019 May 9. No abstract available.

2.

Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD.

Tey SK, Vuckovic S, Varelias A, Martins JP, Olver S, Samson L, Sturgeon E, Leach J, Avery J, Nakagaki M, Butler JP, Curley C, Morton AJ, Durrant ST, Kennedy GA, Hill GR.

Bone Marrow Transplant. 2016 Aug;51(8):1153-5. doi: 10.1038/bmt.2016.83. Epub 2016 Apr 4. No abstract available.

PMID:
27042838
3.

Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial.

Delforge M, Devos T, Rowe J, Español I, Durrant ST, Raddoux J, Boogaerts M, Gramatzki M, Gunther A.

Leuk Lymphoma. 2016 Feb;57(2):470-473. doi: 10.3109/10428194.2015.1055481. Epub 2015 Jul 7. No abstract available.

PMID:
26022523
4.

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, Thomas G, Anderson L, Boyle G, Cloonan N, Leach J, Sturgeon E, Avery J, Olver SD, Lor M, Misra AK, Hutchins C, Morton AJ, Durrant ST, Subramoniapillai E, Butler JP, Curley CI, MacDonald KPA, Tey SK, Hill GR.

Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.

PMID:
25456364
5.

Post transplant CMV-specific T-cell immune reconstitution in the absence of global T-cell immunity is associated with a high risk of subsequent virus reactivation.

Tey SK, Davenport MP, Hill GR, Kennedy GA, Durrant ST, Khanna R, Cromer D.

Bone Marrow Transplant. 2015 Feb;50(2):315-6. doi: 10.1038/bmt.2014.265. Epub 2014 Nov 17. No abstract available.

PMID:
25402417
6.

Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.

Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, Crough T, Durrant ST, Morton JA, Butler JP, Misra AK, Hill GR, Khanna R.

PLoS One. 2013 Oct 11;8(10):e74744. doi: 10.1371/journal.pone.0074744. eCollection 2013.

7.

Potential impact of AUSFTA on Australia's blood supply.

Kennedy GA, Cummings J, Durrant ST.

Med J Aust. 2007 Apr 16;186(8):427; author reply 430. No abstract available.

PMID:
17437402
8.

Successful remission of chronic, refractory autoimmune thrombocytopenic purpura following non-myeloablative allogeneic stem cell transplantation.

Butler JP, Durrant ST, Frost T.

Bone Marrow Transplant. 2003 Apr;31(7):621-2. No abstract available.

PMID:
12692634
9.

Phase III efficacy study of interleukin-3 after autologous bone marrow transplantation in patients with malignant lymphoma.

Brouwer RE, Vellenga E, Zwinderman KH, Bezwoda WR, Durrant ST, Herrmann RP, Kiese B, Maraninchi D, Milligan DW, Sklenar I, Tabilio A, Volonte JL, Winfield DA, Fibbe WE.

Br J Haematol. 1999 Sep;106(3):730-6.

PMID:
10468866
10.

Analgesic infiltration at the site of bone marrow harvest significantly reduces donor morbidity.

Chern B, McCarthy N, Hutchins C, Durrant ST.

Bone Marrow Transplant. 1999 May;23(9):947-9.

12.

Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics.

Lele SS, Durrant ST, Atherton JJ, Moore TD, Thomson HL, Khafagi FA, Frenneaux MP.

Bone Marrow Transplant. 1996 Jun;17(6):1113-8.

PMID:
8807123
13.

Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.

Morton AJ, Durrant ST.

Clin Transplant. 1995 Jun;9(3 Pt 1):205-8.

PMID:
7549062
14.

Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism?

Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant ST.

Br J Rheumatol. 1991 Aug;30(4):301-4.

PMID:
1863830
15.

Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular haemodialysis treatment.

Edmunds ME, Devoy M, Tomson CR, Krishna U, Clayworth A, Durrant ST, Feehally J, Walls J.

Br J Haematol. 1991 Jun;78(2):275-7.

PMID:
2064967
16.

The use of vidarabine in the treatment of human polyomavirus associated acute haemorrhagic cystitis.

Chapman C, Flower AJ, Durrant ST.

Bone Marrow Transplant. 1991 Jun;7(6):481-3.

PMID:
1651795
17.

The clinical relevance of plasma viscosity in Hodgkin's disease.

Akhtar N, Thompson J, Durrant ST, Angel CA, Lauder I, Wood JK.

Clin Lab Haematol. 1991;13(1):1-8.

PMID:
2060259
18.

Histiocytic cytophagic panniculitis.

Hilton DA, O'Malley BP, Durrant ST.

Postgrad Med J. 1990 Nov;66(781):958-61. Review.

19.

Migraine after bone-marrow transplantation.

Gharpure VS, Hutchinson RM, Durrant ST.

Lancet. 1990 Jan 6;335(8680):57. No abstract available.

PMID:
1967366
20.

Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review.

Mathieson PW, O'Neill JH, Durrant ST, Henderson SJ, Green PJ, Newsom-Davis J.

Q J Med. 1990 Jan;74(273):57-61.

PMID:
2326435
21.

In situ hybridization detection of light chain mRNA in routine bone marrow trephines from patients with suspected myeloma.

Akhtar N, Ruprai A, Pringle JH, Lauder I, Durrant ST.

Br J Haematol. 1989 Nov;73(3):296-301.

PMID:
2513865
22.

Zygomycosis in aplastic anaemia: response to a combined regimen of amphotericin B and antilymphocyte globulin.

Rahemtulla A, Durrant ST, Coonar HS, Lee KW, Gordon-Smith EC.

Eur J Haematol. 1988 Apr;40(4):315-7.

PMID:
3366221
23.

Subacute encephalopathy associated with human immunodeficiency virus in haemophilia A.

Rahemtulla A, Durrant ST, Hows JM.

Br Med J (Clin Res Ed). 1986 Oct 18;293(6553):993. No abstract available.

24.

Nafazatrom in treatment of thrombotic thrombocytopenic purpura.

Durrant ST, Joosten P, Gordon-Smith EC.

Lancet. 1985 Oct 12;2(8459):842. No abstract available.

PMID:
2864567

Supplemental Content

Loading ...
Support Center